Mesoblast Ltd has released a press release.
MSB Expands JCR Partnership To Brain Disease In Newborns
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- MSB Provides Q3 Financial Results and Operational Highlights
- Mesoblast Initiates Rolling Submission of BLA for GvHD
- MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
- MSB Licensee Files For Skin Disease Marketing Approval
- MSB Draws US$15 Million From Existing Facility
Later from Mesoblast
- FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
- Circulation Research Highlights MSB Heart Failure Therapy
- Appendix 4C - Quarterly, Strong Commercialization Revenues
- FDA Guidance on Clinical Pathway for LVAD Market Application
- Mesoblast Reports on Annual Results
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast